Amedeo Smart

Free Medical Literature Service

 

Amedeo

Sexually Transmitted Diseases
  Free Subscription

Articles published in
Oral Oncol
    March 2026
  1. CARVALHO WA, Carvalho AA, Silveira AA
    Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
    Oral Oncol. 2026;176:107930.
    >> Share

    February 2026
  2. COSTANTINO A, Bossi P, Uccella S, Spriano G, et al
    Beyond binary ENE in HPV-related oropharyngeal cancer: Toward standardized reporting and risk stratification.
    Oral Oncol. 2026 Feb 27:107909. doi: 10.1016/j.oraloncology.2026.107909.
    >> Share

  3. SHU S
    De-escalation in high-risk HPV-positive OPC: critical appraisal of methodology and inference.
    Oral Oncol. 2026;174:107880.
    >> Share

  4. ARDILA CM, Vivares-Builes AM, Pineda-Velez E
    Frozen section analysis in HPV-associated squamous cell carcinoma of unknown primary: Clinical and pathological considerations.
    Oral Oncol. 2026;174:107878.
    >> Share

    January 2026
  5. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
    Oral Oncol. 2026;174:107858.
    >> Share

  6. SRIDHAR S, Moroco A, Gowrishankar S, Mehrad M, et al
    Accuracy of frozen section for HPV-Associated squamous cell carcinoma of unknown primary.
    Oral Oncol. 2026;174:107861.
    >> Share

    December 2025
  7. YUAN S, Gao J
    Methodological considerations in profiling the immune microenvironment and HPV status of oral multiple primary cancers.
    Oral Oncol. 2025;172:107822.
    >> Share

  8. HACK S, Attal R, Geva K, Farzad A, et al
    Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
    Oral Oncol. 2025;172:107813.
    >> Share

  9. WU J, Zhang J, Lin J, Huo Y, et al
    Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies.
    Oral Oncol. 2025;172:107812.
    >> Share

  10. NYIRJESY SC, Al-Inaya Y, Zhang S, Karadaghy OA, et al
    Incidence of HPV-independent second primary malignancies following treatment of HPV-associated malignancy.
    Oral Oncol. 2025;172:107790.
    >> Share

  11. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
    Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
    Oral Oncol. 2025;171:107792.
    >> Share

  12. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
    Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
    Oral Oncol. 2025;171:107768.
    >> Share

    November 2025
  13. TANG Y, Gan H, Gan X
    The diagnostic trade-off in post-treatment surveillance for HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;172:107798.
    >> Share

  14. LI Y, Kou Q, Zheng C, Nov P, et al
    Hpv-driven rewiring of the tumor immune microenvironment through single-cell profiling informs prognosis and therapy in HNSCC.
    Oral Oncol. 2025;172:107789.
    >> Share

  15. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
    Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
    Oral Oncol. 2025;171:107767.
    >> Share

    October 2025
  16. DAS R, Misra SR, Mohapatra SSG
    Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
    Oral Oncol. 2025;170:107752.
    >> Share

  17. CAO S, Li Q
    Comments on "Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: Long-term follow-up of the quarterback de-escalation trials".
    Oral Oncol. 2025;170:107753.
    >> Share

  18. FENG Z
    Insights on the pilot randomized controlled trial of LEF-SM program for HNC survivors: addressing HPV stratification, adherence measurement, and IMB component dissection.
    Oral Oncol. 2025;170:107748.
    >> Share

  19. MARUDHUPANDI T
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107746.
    >> Share

  20. LI S, Garb BF, Qin T, Soppe SE, et al
    Tumor subtype classification tool for HPV-associated head and neck cancers.
    Oral Oncol. 2025;170:107726.
    >> Share

  21. NASSIF SJ, Longstreth E, Weinstein GS, Kandula S, et al
    Staged transoral surgery in synchronous HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;170:107738.
    >> Share

  22. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    >> Share

    September 2025
  23. MISRA SR, Das R
    Beyond MC1675: The imperative for circulating tumour HPV DNA in personalising adjuvant therapy for oropharyngeal Cancer.
    Oral Oncol. 2025;170:107736.
    >> Share

  24. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers F, et al
    Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2025;170:107685.
    >> Share

  25. ZHOU X, Zhang J, Lou Y, Li W, et al
    Immune and HPV landscape in oral multiple primary cancers compared to single primary cancer.
    Oral Oncol. 2025;169:107646.
    >> Share

  26. KANIMOZHI K
    Commentary on "Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2025 Sep 11:107678. doi: 10.1016/j.oraloncology.2025.107678.
    >> Share

  27. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    >> Share

  28. DUAN Y
    Letter to the Editor: Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107682.
    >> Share

  29. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    >> Share

  30. XU S, Lv Y, He H, Han C, et al
    Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.
    Oral Oncol. 2025;168:107605.
    >> Share

    August 2025
  31. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    >> Share

  32. DUAN Y
    Letter to the editor: Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
    Oral Oncol. 2025;169:107638.
    >> Share

  33. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    >> Share

  34. SHARFUNNISA SH
    Letter to the Editor: "Refining nutritional support in HPV + oropharyngeal cancer: Insights from a predictive modelling approach".
    Oral Oncol. 2025;168:107574.
    >> Share

  35. MA C, Zeng H
    Comment on: "Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States".
    Oral Oncol. 2025;168:107578.
    >> Share

    July 2025
  36. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    >> Share

  37. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    >> Share

  38. KRISHNAN M, Babu S, Rahmathullah A
    Letter to the editor: Toward personalized immunotherapy in OPSCC: Lessons from HPV-driven checkpoint expression.
    Oral Oncol. 2025;168:107547.
    >> Share

  39. SMITH JB, Heiland L, Arnold LD, Simpson MC, et al
    Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
    Oral Oncol. 2025;168:107540.
    >> Share

  40. BABU S, Solomon A, Krishnan M
    Revolutionizing HPV-driven cancer surveillance: A commentary on the validation of the HPV-SEQ liquid biopsy platform.
    Oral Oncol. 2025;168:107527.
    >> Share

  41. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    >> Share

  42. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    >> Share

  43. SINDYA J, Perumal E
    Commentary on "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;168:107494.
    >> Share

  44. SINGARAVEL V
    Prevalence and genotypic patterns of oral HPV infection in Taiwan-A commentary on the PILLOT study and its relevance to Asian public health strategies.
    Oral Oncol. 2025;167:107479.
    >> Share

  45. RAJATHIRAJAN SD
    Commentary on, "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;167:107484.
    >> Share

    June 2025
  46. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    >> Share

  47. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    >> Share

  48. ABILAJI S, Narenkumar J
    Letter to the Editor: Human papilloma virus (HPV) associated oral epithelial dysplasia: Emerging evidence, diagnostic challenges, and future directions.
    Oral Oncol. 2025 Jun 23:107434. doi: 10.1016/j.oraloncology.2025.107434.
    >> Share

  49. SINGH CHAWLA JP
    Comment on "Circulating miRNAs as diagnostic biomarkers in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC)".
    Oral Oncol. 2025;167:107432.
    >> Share

  50. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    >> Share

  51. LIU N, Kuang Y, Kuang R
    Comment on the epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107371.
    >> Share

  52. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    >> Share

    May 2025
  53. RAJATHIRAJAN SD
    Commentary on, "Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2025;166:107394.
    >> Share

  54. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    >> Share

  55. YOU J
    Letter to "Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer".
    Oral Oncol. 2025;166:107345.
    >> Share

  56. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    >> Share

  57. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    >> Share

  58. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    >> Share

    April 2025
  59. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    >> Share

  60. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    >> Share

  61. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    >> Share

  62. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    >> Share

    March 2025
  63. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    >> Share

  64. DSOUZA G, Tewari S, Troy T, Bleyer P, et al
    Oral HPV incidence and risk factors for acquisition.
    Oral Oncol. 2025;163:107249.
    >> Share

  65. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    >> Share

  66. DERMODY SM, Walline H, Bhambhani C, Tewari M, et al
    Addressing knowledge gaps in HPV-related oropharyngeal cancer prevention: A call for action.
    Oral Oncol. 2025;163:107234.
    >> Share

  67. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    >> Share

  68. THAVARAJ S, Henley-Smith R, Gregson-Williams H, Yogarajah S, et al
    Clinico-pathological characterisation of human papillomavirus-associated oral epithelial dysplasia.
    Oral Oncol. 2025;162:107182.
    >> Share

    February 2025
  69. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    >> Share

  70. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    >> Share

    January 2025
  71. XU S, Qin F, Hu W
    Comment on, "Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy".
    Oral Oncol. 2025;161:107186.
    >> Share

  72. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    >> Share

  73. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    >> Share

    December 2024
  74. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    >> Share

  75. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    >> Share

    November 2024
  76. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    >> Share

  77. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    >> Share

  78. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    >> Share

    October 2024
  79. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    >> Share

  80. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    >> Share

  81. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    >> Share

  82. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    >> Share

    September 2024
  83. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    >> Share

  84. SANKAR S
    Letter to Editor regarding "Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer".
    Oral Oncol. 2024;159:107020.
    >> Share

    August 2024
  85. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    >> Share

  86. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    >> Share

    July 2024
  87. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    >> Share

  88. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    >> Share

  89. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    >> Share

  90. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    >> Share

    June 2024
  91. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    >> Share

  92. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    >> Share

  93. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    >> Share

  94. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    >> Share

    May 2024
  95. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    >> Share

    April 2024
  96. WATON A, Chambers A, Fox H, O'Hara J, et al
    Human Papilloma Virus-16 associated primary adenocarcinoma of the tonsil: Report of two cases and literature review.
    Oral Oncol. 2024;151:106766.
    >> Share

    March 2024
  97. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    >> Share

  98. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    >> Share

  99. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    >> Share

    February 2024
  100. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    >> Share

  101. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
    Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
    Oral Oncol. 2024;149:106675.
    >> Share

    January 2024
  102. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
    Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
    Oral Oncol. 2024;148:106644.
    >> Share

    December 2023
  103. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
    Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
    Oral Oncol. 2023;149:106676.
    >> Share

    November 2023
  104. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
    Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
    Oral Oncol. 2023;148:106645.
    >> Share

  105. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
    Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
    Oral Oncol. 2023;146:106568.
    >> Share

    October 2023
  106. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
    Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
    Oral Oncol. 2023;147:106584.
    >> Share

    September 2023
  107. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
    Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2023;146:106580.
    >> Share

  108. SINGH R, Song S
    Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2023;146:106493.
    >> Share

  109. SHAH R, Tyagi S, Liu C, Judson B, et al
    Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
    Oral Oncol. 2023;146:106564.
    >> Share

    August 2023
  110. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
    Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
    Oral Oncol. 2023;146:106555.
    >> Share

  111. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
    Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
    Oral Oncol. 2023;143:106436.
    >> Share

    July 2023
  112. NEWMAN S, Cowart JH, Omar N, Martin E, et al
    HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
    Oral Oncol. 2023;145:106526.
    >> Share

  113. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
    Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
    Oral Oncol. 2023;144:106487.
    >> Share

  114. DAHLSTROM KR, Sikora AG, Liu Y, Chang CC, et al
    Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
    Oral Oncol. 2023;142:106401.
    >> Share

    May 2023
  115. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
    Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
    Oral Oncol. 2023;141:106417.
    >> Share

    April 2023
  116. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
    Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
    Oral Oncol. 2023;141:106399.
    >> Share

    March 2023
  117. ZUO N, Ma L, Liu T, Hu W, et al
    Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2023;140:106367.
    >> Share

  118. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
    Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;140:106361.
    >> Share

  119. ZHANG L, Freeman T, Sun S, Bhateja P, et al
    The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2023;139:106357.
    >> Share

  120. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
    Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
    Oral Oncol. 2023;138:106311.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016